These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36731023)

  • 21. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
    Jamieson A; McConechy MK; Lum A; Leung S; Thompson EF; Senz J; Talhouk A; Huntsman DG; Bashashati A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2023 Aug; 175():45-52. PubMed ID: 37321155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
    Wu Q; Zhang N; Xie X
    BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
    Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
    Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting.
    Casey L; Singh N
    Int J Gynecol Pathol; 2021 Jan; 40(1):5-16. PubMed ID: 33290350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular characterization in the prediction of disease extent in endometrial carcinoma.
    Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
    Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
    Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
    Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
    Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma].
    Du NN; Liu Y; Ren CX; Wang YX; Du J; Yang J; Liu CR
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):596-603. PubMed ID: 31422589
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
    Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
    Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
    Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
    Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review.
    De Vitis LA; Schivardi G; Caruso G; Fumagalli C; Vacirca D; Achilarre MT; Aloisi A; Garbi A; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Bogani G; Colombo N; Multinu F; Betella I
    Int J Gynecol Cancer; 2024 Feb; 34(2):229-238. PubMed ID: 38135437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.
    Hoang LN; Kinloch MA; Leo JM; Grondin K; Lee CH; Ewanowich C; Köbel M; Cheng A; Talhouk A; McConechy M; Huntsman DG; McAlpine JN; Soslow RA; Gilks CB
    Am J Surg Pathol; 2017 Feb; 41(2):245-252. PubMed ID: 28079598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
    Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
    Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
    Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
    Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
    Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma: A Clinicopathologic and Molecular Analysis of 9 Tumors Based on the TCGA Classifier.
    Safdar NS; Thompson EF; Gilks CB; Isacson C; Bennett JA; Clarke B; Young RH; Oliva E
    Am J Surg Pathol; 2021 Aug; 45(8):1038-1046. PubMed ID: 34115671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
    Pasanen A; Loukovaara M; Bützow R
    Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
    Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
    Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.